I recently was rifling through some old files of news clippings (you remember those pesky things, don’t you?) and came across a major New York Times Magazine feature from 1983. It was titled, “Toward the Conquest of Heart Disease.”
Three decades ago, as the article describes, the main treatments were surgical: valve replacement and the “far more complicated, technically demanding” bypass graft surgery. The author, Harry Schwartz, also identifies some exciting new advances in heart disease treatment: artificial hearts, heart transplants, new drugs, something called nuclear magnetic resonance (N.M.R.) that was “being used in a handful of hospitals” (today we call it MRI!). Continue reading
Rumors and theories about an acquisition of Volcano Corporation (NASDAQ: VOLC) had been circulating for quite some time: months, years even. The company seemed an obvious choice: it has an advanced intravascular ultrasound (IVUS) technology that leads the market, with Boston Scientific coming in second; it has a fractional flow reserve (FFR) wire that splits the market with St. Jude Medical; and recently 
Almost two decades ago, interventional cardiology pioneer Dr. Spencer B. King III penned an article for Circulation titled, “
Today is Veterans Day in the U.S., honoring the soldiers who fought in the country’s wars. Last week was the VIVA 14 meeting, presenting the latest advances and techniques in endovascular repair and therapy of blood vessels.
RSS Feed
